Business Standard

Saturday, December 21, 2024 | 10:41 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

US lawsuit may not impact India launch of Gennova's mRNA vaccine

The vaccine is now under review by the regulator, and if approved, it may be ready for launch in the Indian market and will be the first mRNA Covid vaccine to be available here.

vaccination
Premium

Sohini Das Mumbai
The lawsuit in a Seattle court by a US start-up may not immediately impact the launch of Pune-based Gennova Biopharmaceuticals’ mRNA vaccine HGCO19 once it receives the Indian regulator’s nod, feel legal experts.

The long-term prospects of the vaccine may depend on how the case progresses. Gennova already submitted phase 2/3 clinical trial data with the Drugs Controller General of India (DCGI) this month.

The vaccine is now under review by the regulator, and if approved, it may be ready for launch in the Indian market. It will be the first mRNA Covid vaccine to be available here.

Meanwhile, US firm HDT Bio

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in